Seeing Is Believing
RNAZ is currently covered by 1 analysts with an average price target of $7.16. This is a potential upside of $0.02 (0.28%) from yesterday's end of day stock price of $7.14.
Transcode Therapeutics's activity chart (see below) currently has 2 price targets and 13 ratings on display. The stock rating distribution of RNAZ is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 87.5% with an average time for these price targets to be met of 80 days.
Highest price target for RNAZ is $10, Lowest price target is $10, average price target is $10.
Most recent stock forecast was given by EMILY BODNAR from HC WAINWRIGHT on 16-Apr-2025. First documented stock forecast 07-Jun-2022.
Currently out of the existing stock ratings of RNAZ, 11 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$10
$2.86 (40.06%)
$20
1 months 22 days ago
(16-Apr-2025)
7/8 (87.5%)
$0.02 (0.20%)
80
What is RNAZ (Transcode Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on RNAZ (Transcode Therapeutics) with a proven track record?
Which analyst has the most public recommendations on RNAZ (Transcode Therapeutics)?
Which analyst is the currently most bullish on RNAZ (Transcode Therapeutics)?